Metachronous Peritoneal Metastases After Adjuvant Chemotherapy are Associated with Poor Outcome After Cytoreduction and HIPEC.

摘要: Cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) improve the survival of colorectal cancer (CRC) patients with peritoneal metastases. Patient selection is key since this treatment associated high morbidity. Patients recurrence within 1 year after previous adjuvant are thought to benefit less from HIPEC treatment; however, no published data available assist in clinical decision making. This study assessed whether was treatment. Peritoneal chemotherapy, as well other potentially prognostic pathological variables, were tested univariate multivariate analysis for correlation primary outcomes, i.e. overall (OS) disease-free (DFS). Two prospectively collected databases VU University Medical Center Amsterdam Catherina Hospital Eindhoven containing 345 CRC treated intent utilized. High Cancer Index (PCI) scores worse DFS [hazard ratio (HR) 1.04, 95% confidence interval (CI) 1.00–1.08, p = 0.040] OS (HR 1.11, CI 1.07–1.15, p < 0.001) analysis. Furthermore, following had 2.13, 1.26–3.61, p = 0.005) 2.76, 1.45–5.27, p = 0.002) than who did not receive or 1 year. PCI scores, poor cytoreduction HIPEC. These factors should be considered order avoid high-morbidity might such